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ABSTRACT
Background. Inflammation is a hallmark of chronic kidney dis-
ease (CKD) and stimulates glomerular expression of vascular
adhesion molecules (VCAMs). We investigated in a general
population whether estimated glomerular filtration rate (eGFR)
is associated with circulating adhesion molecules, inflammation
markers or both.
Methods.Wemeasured serum levels of five adhesion molecules
[VCAM-1, intracellular adhesion molecule-1 (ICAM-1),
P-selectin, E-selectin and monocyte chemoattractant protein-1
(MCP-1)] and seven inflammation markers [C-reactive protein
(CRP), neutrophil gelatinase-associated lipocalin (NGAL),
tumour necrosis factor receptor 1 (TNF-R1), TNF-a, interleu-
kin 6 (IL-6), IL-8 and vascular endothelial growth factor] in
1338 randomly recruited people (50.8% women, mean age
51.7 years, eGFR 79.9mL/min/1.73 m2).
Results. In multivariable-adjusted analyses, eGFR decreased
(P 0.004) with higher VCAM-1 (association size expressed in
mL/min/1.73 m2 for a doubling of the marker, 2.99), MCP-1
(1.19), NGAL (1.19), TNF receptor 1 (2.78), TNF-a
(2.28) and IL-6 (0.94). The odds ratios of having eGFR<60
versus60mL/min/1.73 m2 (n¼ 138 versus 1200) were signifi-
cant (P 0.001) for VCAM-1 (1.77), MCP-1 (1.32), NGAL
(1.26), TNF-R1 (1.49), TNF-a (1.45) and IL-6 (1.20). Compared
with 24-h albuminuria, VCAM-1 increased (P<0.0001) the
area under the curve from 0.57 to 0.65, MCP-1 to 0.67 and
TNF-R1 to 0.79, but TNF-R1 outperformed both adhesion mol-
ecules (P< 0.0001).
Conclusions. In a general population, eGFR is inversely associ-
ated with circulating adhesion molecules VCAM-1 and MCP-1
and several inflammation markers, but inflammation markers,
in particular TNF-R1 and TNF-a, identify patients with
eGFR<60mL/min/1.73 m2 more accurately.
Keywords: adhesion molecules, eGFR, inflammation, popula-
tion science, renal function
INTRODUCTION
The Global Burden of Disease Study 2010 estimated that 0.40
million of nearly 50 million deaths occurring annually world-
wide, were attributable to chronic kidney disease (CKD) in
1990 and 0.74 million in 2010, representing an increase of
82.3% [1]. CKD is therefore a major health problem affecting
the quality of life of millions of people and draining health
care resources [1–3]. The discovery of biomarkers that allow
screening for asymptomatic renal disease or predict a decline
in the estimated glomerular filtration rate (eGFR) is main-
stream in current CKD research with the goal to curtail the
epidemic [1, 2].
Inflammation is a hallmark of deteriorating renal function
[4–6]. In activated glomerular endothelial cells, inflammation
induces expression of adhesion molecules, which in turn add to
VC The Author 2017. Published by Oxford University Press on behalf of
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|the renal injury [7]. Vascular adhesion molecule-1 (VCAM-1)
is constitutively expressed in Bowman’s capsule and in proximal
tubules [8–10]. Inflammation stimuli, such as tumour necrosis
factor a (TNF-a) and advanced glycation products enhance its
expression [8–10]. Likewise, in glomeruli of diabetic mice,
monocyte chemoattractant protein-1 (MCP-1) is upregulated
and enhances disruption of glomerular membranes, thereby
leading to albuminuria [11, 12]. Few human studies have ad-
dressed the question of whether adhesion molecules are associ-
ated with glomerular dysfunction or predict its decline. These
studies mainly enrolled patients with hypertension, diabetes
mellitus [6], vascular disease [13] or glomerulonephritis [14]
and involved measurement of a relatively limited number of
biomarkers, often including C-reactive protein (CRP). Building
on experimental studies [8–12] and research in patients [6, 13,
14], we analyzed the database of the Flemish Study on
Environment, Genes and Health Outcomes (FLEMENGHO)
[15, 16]. Our objective was to investigate in cross-sectional and
longitudinal analyses whether glomerular dysfunction is differ-
entially associated with circulating adhesion molecules, inflam-
mation markers or both.
MATERIALS AND METHODS
Study population
FLEMENGHO complies with the Helsinki Declaration [17]
for research in human subjects. The Ethics Committee of the
University of Leuven approved the study [18]. Recruitment
started in 1985 and continued until 2004. FLEMENGHO par-
ticipants represent a family-based population sample randomly
selected from a geographically defined area in Northern
Belgium [15, 16]. The initial participation rate was 78.0%. The
participants were repeatedly followed up at the field centre in
the catchment area (North Limburg, Belgium). From 2005 to
2010 (examination cycle A) and from 2010 to 2014 (examina-
tion cycle B), we mailed an invitation letter to 1208 and 1043
former participants, respectively, for a follow-up examination (
Figure 1), including an assessment of renal function. However,
of the individuals invited for examination cycles A and B, 153
and 91 were unavailable because they had died (n¼ 26 and 38),
had been institutionalized or were too ill (n¼ 27 and 24) or had
moved out of the area or did not respond (n¼ 100 and 29). Of
the remaining 1050 and 952 former participants, 828 and 718
renewed informed consent (participation rates 78.5% and
75.4%, respectively). Of examination cycle A and B participants,
we excluded 165 and 45, because the biobank of serum samples
was exhausted so that the circulating biomarkers could not be
measured (n¼ 149 and 0) or because the circulating biomarkers
were either missing (n¼ 6 and 34) or exceeded the mean by
3 standard deviations (SDs) (n¼ 10 and 11). The number of
examination cycle A (n¼ 665) and B (n¼ 673) participants
available for the cross-sectional analyses therefore totalled 1338.
Of 665 examination cycle A participants, 500 took part in a
follow-up assessment of their renal function and were included
in the longitudinal analyses. At each contact participants re-
newed their informed written consent.
Assessment of renal function
We measured the concentration of creatinine in serum us-
ing Jaffe’s method [19] with modifications described else-
where [20, 21] on automated analysers in a single certified
laboratory that applied isotope-dilution mass spectrometry
FIGURE 1: Flowchart of participants included in the cross-sectional and longitudinal analyses.
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|for calibration of the serum creatinine measurements. We de-
rived eGFR from serum creatinine by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) [22] equa-
tion. We staged eGFR according to the National Kidney
Foundation [Kidney Disease Outcomes Quality Initiative
(KDOQI)] guideline [23] as eGFR90, 60–89, 45–59, 30–44,
15–29 and <15mL/min/1.73m2 for Stages 1, 2, 3, 4 and 5, re-
spectively. Participants collected a timed 24-h urine sample
for the measurement of albumin. Micro- and macro-
albuminuria were 24-h excretions ranging from 30 to 300mg
or >300mg, respectively. Guideline-based staging of CKD
[23] requires repeat measurement of eGFR or albuminuria or
additional evidence for renal disease. However, as this is im-
practicable in the context of population studies due to multi-
ple visits comprising the participation rate, staging of CKD in
our current study, as done in landmark epidemiological re-
search [24, 25], relies on a single serum sample to determine
eGFR and a single urine sample collection to determine albu-
minuria at baseline and follow-up.
Serum biomarkers
The Evidence Investigator system (Randox, Belfast, UK) uses
Biochip Array Technology to detect several analytes from a sin-
gle sample. For this study, the following arrays were employed
Adhesion [VCAM-1, intracellular adhesion molecule-1
(ICAM-1), P-selectin, E-selectin], Cerebral II (CRP, NGAL,
TNF-R1) and Cytokine High Sensitivity [interleukin 6 (IL-6),
IL-8, vascular endothelial growth factor (VEGF), MCP-1, TNF-
a] utilizing the sandwich assay format [26–29]. Prior to analy-
sis, serum samples were defrosted and preserved on ice. A single
serum aliquot was provided for all arrays. Therefore all panels
were commenced within 1 h of defrosting to minimize degrada-
tion. Concentrations of individual analytes were determined by
Biochip Array Technology according to the manufacturer’s in-
structions (Adhesion Molecule Array EV3519, Cerebral Array
II EV3637 and Cytokine and Growth Factors Array (High
Sensitivity) EV3623]. The Supplementary data gives detailed in-
formation on the processing of the samples.
Other measurements
At baseline, nurses administered a questionnaire to collect
detailed information on each participant’s medical history,
smoking and drinking habits and intake of medications. The
conventional blood pressure was the average of five consecu-
tive auscultatory readings obtained with the subject in a
seated position. Mean arterial pressure was diastolic blood
pressure plus one-third of the difference between systolic and
diastolic blood pressure. Hypertension was a blood pressure
of at least 140mmHg systolic or 90mmHg diastolic or use of
antihypertensive drugs. Body mass index was weight in kilo-
grams divided by the square of height in metres. A venous
blood sample was obtained after the participants had been
fasting for 6–8 h for measurement of plasma glucose, serum
total and high-density lipoprotein (HDL) cholesterol and se-
rum c-glutamyltransferase as an index of alcohol intake.
Diabetes mellitus was a self-reported diagnosis, a fasting glu-
cose level of at least 126mg/dL or the use of antidiabetic
agents [30].
Statistical analyses
For database management and statistical analysis we used
SAS version 9.4 (SAS Institute, Cary, NC, USA). Means were
compared using the large-sample z-test and proportions by
Fisher’s exact test. We normalized the distributions of c-glu-
tamyltransferase, 24-h microalbuminuria and all circulating
biomarkers by a logarithmic transformation. We identified
baseline covariables to be retained in the analyses by a step-
wise regression procedure with P-values for covariables to en-
ter and stay in the models set at 0.15. We considered as
potential covariables mean arterial pressure, body mass in-
dex, waist:hip ratio, smoking, plasma glucose, serum c-gluta-
myltransferase, the total:HDL cholesterol ratio, 24-h
microalbuminuria and the use of diuretics, inhibitors of the
renin–angiotensin system [b-blockers, angiotensin-
converting enzyme (ACE) inhibitors and angiotensin type 1
receptor blockers), vasodilators (calcium channel blockers
and a-blockers) and lipid-lowering drugs (fibrates and sta-
tins). Using principal component analysis, we also combined
adhesion molecules and inflammation markers of interest
into a single normally distributed variable.
In continuous analyses, we standardized eGFR to the aver-
age in the whole study population (mean or ratio) of the
covariables measured at baseline as identified by stepwise re-
gression. We did not adjust eGFR for sex and age, because
these variables are already included in the CKD-EPI formula
[22]. Using linear regression, standardized eGFR at baseline
(n¼ 1338) and standardized eGFR at follow-up (n¼ 500)
were regressed on the biomarkers measured at baseline.
Models with eGFR at follow-up, as a dependent variable, were
additionally adjusted for follow-up duration. The relative
risks of having eGFR<60 versus 60mL/min/1.73 m2 at
baseline (n¼ 138 of 1338) or to experience over follow-up a
decline in eGFR from60 to <60mL/min/1.73 m2 (n¼ 55 of
500) were modelled in relation to the biomarkers and covari-
ables measured at baseline using logistic or Cox regression,
respectively. These models accounted for the same baseline
covariables as mentioned earlier. The results of these cross-
sectional and longitudinal analyses of continuous (eGFR) and
categorical (eGFR stage) outcomes were summarized in
log10 probability plots. Finally, we evaluated the potential
of 24-h albuminuria and circulating VCAM-1, MCP-1 and
TNF-R1, as measured at baseline to discriminate between
participants whose eGFR declined from60mL/min/1.73 m2
at baseline to<60mL/min/1.73 m2 at follow-up by construct-
ing receiver operating characteristic (ROC) curves and by cal-
culating the area under the curve (AUC). The 95% confidence
interval (CI) of the AUC was calculated by the DeLong
method.
RESULTS
Characteristics of participants
Participant age averaged 51.7 years (range 15–90) and the
proportion of women was 50.8%. Of 1338 participants, 426
(31.8%) had hypertension, of whom 345 (25.8%) were on
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antihypertensive drug treatment, 222 (16.6%) were taking lipid-
lowering drugs and 55 (4.1%) had diabetes (Supplementary
data, Table S1). Among 345 patients on antihypertensive drug
treatment, 127 (36.8%) took diuretics, 277 (80.3%) inhibitors of
the renin system, 89 (25.8%) vasodilators and 153 (44.3%) were
on combination therapy with more than one drug class. Of 222
patients on lipid-lowering treatment, 13 (5.9%) took fibrates
and 210 (94.6%) used statins. Compared with examination
cycle A participants (Supplementary data, Table S1), people ex-
amined in examination cycle B were 3.9 years older (49.7 versus
53.6 years) and therefore had a higher waist:hip ratio (0.87 ver-
sus 0.89), elevated systolic/diastolic blood pressure (128.1/79.6
versus 132.7/82.0mmHg) and a higher prevalence of hyperten-
sion (25.5% versus 38.6%), treated hypertension (22.9% versus
27.9%) and use of lipid-lowering drugs (14.0% versus 19.0%)
but lower glomerular filtration rate (eGFR 81.1 versus 78.8mL/
min/1.73 m2) and smoking prevalence (20.0 versus 13.5%).
Tables 1 and 2 summarize the characteristics of participants
and the circulating markers of eGFR by quartiles, respectively.
Supplementary data, Table S2 lists the characteristics of partici-
pants by quartiles of the distribution of VCAM-1, the adhesion
molecule reported in several experimental studies [8–10]. Age,
body mass index, the waist:hip ratio, the proportion of partici-
pants on antihypertensive drug treatment, serum creatinine and
total cholesterol and plasma glucose increased (0.062 P
0.001) with a higher category of VCAM-1, whereas the propor-
tion of women (P¼ 0.019) and eGFR (P¼ 0.051) decreased.
The serum levels of ICAM-1, P-selectin, TNF-R1, TNF-a and
IL-6 increased (0.0018 P 0.087) across quartiles of the
VCAM-1 distribution (Supplementary data, Table S3).
Across quartiles of the MCP-1 [11, 12] distribution
(Supplementary data, Table S4), blood pressure, the prevalence
of hypertension and treated hypertension (0.057 P 0.004),
heart rate (P¼ 0.095), serum creatinine (P¼ 0.079) and the risk
of diabetes mellitus (P¼ 0.032) increased, whereas eGFR de-
creased (P¼ 0.013). Among all participants, 47 (3.5%) had
micro-albuminuria and 5 (0.4%) had macro-albuminuria, but
trends across VCAM-1 (Supplementary data, Table S2) and
MCP-1 (Supplementary data, Table S4) distributions did not
reach significance. Along similar lines, across quartiles of the
MCP-1 distribution, VCAM-1 (P¼ 0.037) and E-selectin
(P¼ 0.025) and all inflammation markers (0.0001< P 0.
0789) increased (Supplementary data, Table S5).
eGFR stage at baseline and follow-up
At baseline, of 1338 participants, 346 (25.9%) were in eGFR
Stage 1, 854 (63.8%) in Stage 2, 112 (8.4%) in Stage 3 and 26
(1.9%) in Stage 4. The median interval from baseline to follow-
up in 500 participants with a second eGFR assessment available
was 4.7 years (5th–95th percentile interval 3.7–5.2). In these 500
participants, eGFR decreased by 1.04mL/min/1.73 m2/year.
Of 145 participants with eGFR Stage 1 at baseline, 71 (49.0%)
maintained Stage 1 and 74 (51.0%) progressed to Stage 2. Of
322 participants with Stage 2 at baseline, 22 (6.8%) regressed to
Stage 1, 267 (82.9%) remained in Stage 2 and 33 (10.3%) prog-
ressed to Stage 3. Of 33 participants with Stage 3 at baseline, 3
(9.1%) regressed to Stage 2 and 30 (90.9%) stayed in Stage 3. At
follow-up, none of the 500 participants had progressed to Stage
4 or 5. Compared with the 500 examination cycle A participants
Table 1. Characteristics of 1338 participants by quartiles of eGFR
Characteristic Low Medium low Medium high High P-value
Limits (mL/min/1.73 m2) <69.89 69.89–79.73 79.73–90.77 90.77
Participants in category, n 335 334 334 334
Women, n (%) 200 (59.7) 172 (51.5)* 176 (52.5) 132 (39.5)‡ 0.08
Smokers, n (%) 34 (10.2) 50 (15.0) 58 (17.3)* 81 (24.3)§ 0.02
Hypertension, n (%) 180 (53.7) 107 (32.0)§ 94 (28.1) 62 (18.6)† 0.050
Antihypertensive treatment, n (%) 163 (48.7) 76 (22.8)§ 61 (18.2) 24 (7.2)§ 0.052
Lipid-lowering treatment, n (%) 101 (30.2) 65 (19.5)† 40 (11.9)† 16 (4.8)‡ 0.01
Diabetes mellitus, n (%) 23 (6.9) 13 (3.9) 12 (3.6) 7 (2.1) 0.056
Age (years), mean (SD) 66.0 (10.9) 55.4 (12.3)§ 48.2 (12.6)§ 37.0 (12.5)§ 0.003
Body mass index (kg/m2), mean (SD) 28.0 (4.6) 26.9 (4.5)† 26.2 (4.2)* 25.2 (4.0)† 0.003
Waist:hip ratio, mean (SD) 0.90 (0.08) 0.89 (0.08) 0.87 (0.08)† 0.85 (0.08)† 0.001
Office blood pressure (mmHg), mean (SD)
Systolic pressure 139.1 (18.3) 131.7 (15.7)§ 128.2 (16.7)† 122.9 (14.2)§ 0.01
Diastolic pressure 81.0 (9.8) 82.2 (9.3) 82.3 (9.6) 77.8 (9.6)§ 0.42
Mean arterial pressure 100.3 (10.2) 98.7 (10.0)* 97.6 (11.0) 92.8 (10.1)§ 0.057
Heart rate (beats/min), mean (SD) 63.7 (9.3) 63.1 (9.4) 64.7 (9.8)* 63.9 (9.3) 0.57
Biochemical data, mean (SD)
Serum creatinine (lmol/L) 98.3 (16.8) 87.4 (11.4)§ 82.1 (11.0)§ 78.1 (10.3)§ 0.03
24-h microalbuminuria (mg) 6.0 (4.5–8.3) 6.2 (4.5–8.1) 5.7 (4.2–8.1) 5.6 (3.9–7.6) 0.20
Total cholesterol (mmol/L) 5.14 (0.99) 5.17 (0.93) 5.07 (0.91) 4.81 (0.95)† 0.14
HDL cholesterol (mmol/L) 1.45 (0.40) 1.47 (0.40) 1.50 (0.39) 1.45 (0.35) 0.84
Total:HDL cholesterol ratio 3.75 (1.06) 3.71 (1.03) 3.59 (1.07) 3.49 (1.03) 0.02
Plasma glucose (mmol/L) 5.04 (0.90) 4.85 (0.81)† 4.80 (0.67) 4.64 (0.52)‡ 0.02
c-glutamyltransferase (units/L) 22 (15–31) 21 (15–33) 19 (13–28)* 18 (13–27) 0.01
eGFR according to the CKD-EPI formula [22]. Office blood pressure was the average of five consecutive auscultatory readings. Hypertension was a blood pressure  140mmHg systolic
or 90mmHg diastolic or the use of antihypertensive drugs. For 24-h microalbuminuria and c-glutamyltransferase, values are geometric mean (interquartile range). P-values are for
linear trend across eGFR categories. Significance of the difference with the adjacent lower fourth: *P 0.05, †P 0.01, ‡P 0.001, §P 0.0001.
G l o m e r u l a r f u n c t i o n a n d c i r c u l a t i n g b i o m a r k e r s 429Downloaded from https://academic.oup.c m/ndt/article-abstract/33/3/426/4093229
by University of Glasgow user
on 12 March 2018
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
with follow-up, the 165 without follow-up had similar baseline
characteristics (Supplementary data, Table S1; P 0.18).
Cross-sectional analyses of the baseline data in 1338
participants
Based on the stepwise regression procedure (Supplementary
data, Table S6), we adjusted the cross-sectional associations be-
tween eGFR and the biomarkers under study for mean arterial
pressure, waist:hip ratio, smoking, plasma glucose, c-glutamyl-
transferase, total:HDL cholesterol ratio, 24-h microalbuminuria
and use of diuretics, inhibitors of the renin–angiotensin system
(b-blockers, ACE inhibitors and angiotensin type 1 receptor
blockers) and vasodilators (calcium channel blockers and
a-blockers) and lipid- lowering drugs.
In the cross-sectional analysis of the baseline data (Table 3),
with adjustments applied for covariables (Supplementary data,
Table S6), standardized eGFR was inversely correlated with cir-
culating VCAM-1 (P< 0.0001), MCP-1 (P¼ 0.002), neutrophil
gelatinase-associated lipocalin (NGAL; P¼ 0.002), TNF recep-
tor 1 (TNF-R1; P< 0.0001), TNF-a (P< 0.0001) and IL-6
(P¼ 0.004). The association sizes (expressed in mL/min/1.73
m2) for a doubling of the biomarker were 2.99 for VCAM-1,
1.19 for MCP-1, 1.19 for NGAL, 2.78 for TNF-R1, 2.28
for TNF-a and 0.94 for IL-6. In the categorical analysis of the
baseline data, the multivariable-adjusted odds ratios expressing
the risk of having eGFR<60mL/min/1.73 m2 (n¼ 138) versus
60mL/min/1.73 m2 (n¼ 1200) for a doubling of the bio-
markers were 1.77 (P< 0.0001) for VCAM-1, 1.32 (P< 0.0001)
for MCP-1, 1.26 (P¼ 0.0002) for NGAL, 1.49 (P< 0.0001) for
TNF-R1, 1.45 (P< 0.0001) for TNF-a, 1.20 (P< 0.0008) for IL-
6 and 1.12 (P¼ 0.036) for VEGF. Figure 2 shows thelog10(P)
probability plot of the multivariable-adjusted association of var-
ious markers with eGFR (continuous) or eGFR stage (<60 ver-
sus 60mL/min/1.73 m2) in the cross-sectional analyses of the
baseline data.
Figure 3 shows the AUC for the adhesion molecules and in-
flammation markers in the discrimination between eGFR<60
versus60mL/min/1.73 m2 at baseline. Compared with 24 h-
microalbuminuria, the AUC was significantly greater for adhe-
sion molecules MCP-1 (P¼ 0.003) and VCAM-1 (P¼ 0.024)
and for the inflammation markers TNF-R1 (P< 0.0001), TNF-
a (P< 0.0001), IL-6 (P¼ 0.016) and NGAL (P¼ 0.028). Using
24-h albuminuria as a reference (Figure 4), VCAM-1 increased
the AUC from 0.57 (95% CI 0.52–0.62; P¼ 0.024) to 0.65 (95%
CI 0.60–0.70; P¼ 0.024), MCP-1 to 0.67 (95% CI 0.63–0.71;
P¼ 0.003), TNF-R1 to 0.79 (95% CI, 0.75–0.83; P<0.0001) and
TNF-a to 0.73 (95% CI 0.69–0.77; P<0.0001). There was no
difference between the AUC associated with the two adhesion
molecules, but TNF-R1 outperformed VCAM-1 (P< 0.0001)
Table 2. Circulating biomarkers by quartiles of eGFR
Characteristic Low Medium low Medium high High P-value
Limits (mL/min/1.73 m2) <69.89 69.89–79.73 79.73–90.77 90.77
Participants in category, n 335 334 335 334
Adhesion molecules
VCAM-1 (ng/mL) 592 (469–731) 524 (433–666)‡ 496 (417–626) 507 (410–642) 0.15
ICAM-1 (ng/mL) 251 (209–310) 244 (201–295) 235 (196–285) 239 (198–297) 0.16
E-selectin (ng/mL) 15 (11–21) 15 (11–20) 15 (12–21) 16 (12–20) 0.23
P-selectin (ng/mL) 145 (113–180) 141 (106–169) 132 (103–164) 131 (103–164) 0.039
MCP-1 (pg/mL) 187 (127–239) 161 (110–231)* 212 (148–212) 136 (97–192) 0.60
Inflammation markers
CRP (ng/mL) 1.52 (1.03–2.77) 1.32 (0.89–2.48) 1.22 (0.85–2.23) 1.24 (0.85–2.59) 0.11
NGAL (ng/mL) 387 (278–573) 359 (241–522) 342 (232–518) 308 (217–491) 0.007
TNF-R1 (ng/mL) 0.82 (0.69–1.01) 0.70 (0.60–0.84)† 0.67 (0.55–0.78) 0.64 (0.53–0.75) 0.067
TNF-a (pg/mL) 8.2 (6.9–9.7) 7.4 (6.1–8.7)§ 6.8 (5.8–8.4) 6.7 (5.6–8.03) 0.046
IL-6 (pg/mL) 2.00 (1.28–3.31) 1.61 (1.06–2.50)† 1.48 (0.99–2.46) 1.43 (0.93–2.44) 0.080
IL-8 (pg/mL) 9.1 (6.2–12.9) 8.4 (6.1–11.4) 8.2 (5.8–12.2) 7.6 (5.4–11.0) 0.019
VEGF (pg/mL) 64 (37–112) 53 (31–98)† 54 (36–101) 51 (31–91) 0.15
Values are geometric means (interquartile range). P-values are for the linear trend across eGFR categories. Significance of the difference with the adjacent lower fourth: *P 0.05,
†P 0.01, ‡P 0.001, §P 0.0001.
Table 3. Multivariable-adjusted associations of eGFR with the biomarkers
measured at baseline
Biomarker
(baseline)
eGFR at baseline
(n ¼ 1338),
estimate (95% CI)
eGFR at follow-up
(n ¼ 500),
estimate (95% CI)
Adhesion molecules
VCAM-1 (ng/mL) –2.99 (–4.49 to –1.50)§ –2.76 (–5.30 to –0.22)*
ICAM-1 (ng/mL) –1.05 (–2.68 – 0.57) –0.38 (–2.92 – 2.15)
E-selectin (ng/mL) 1.43 (0.27–2.59)* 0.44 (–1.26 – 2.14)
P-selectin (ng/mL) –1.25 (–2.65 – 0.15) –1.40 (–3.66 – 0.86)
MCP-1 (pg/mL) –1.19 (–1.95 to –0.42)† –2.90 (–4.28 to –1.52)§
Inflammation markers
CRP (ng/mL) –0.45 (–1.01 – 0.10) –0.63 (–1.61 – 0.35)
NGAL (ng/mL) –1.19 (–1.93 to –0.45)† –1.28 (–2.51 to –0.06)*
TNF-R1
(ng/mL)
–2.78 (–3.79 – 1.77)§ –5.34 (–7.52 to –3.16)§
TNF-a (pg/mL) –2.28 (–3.35 – 1.20)§ –6.99 (–9.26 to –4.72)§
IL-6 (pg/mL) –0.94 (–1.57 to –0.30)† –1.31 (–2.39 to –0.22)*
IL-8 (pg/mL) –0.31 (–1.06 – 0.44) –1.62 (–2.88 to –0.35)*
VEGF (pg/mL) –0.63 (–1.24 to –0.01) –0.84 (–1.93 – 0.25)
eGFR calculated according to the CKD-EPI formula [22]; Estimates, given with 95% CI,
express the difference in eGFR associated with a doubling of the marker. The analyses
were adjusted for baseline covariables, including mean arterial pressure, waist:hip ratio,
smoking, plasma glucose, c-glutamyltransferase, total:HDL cholesterol ratio, 24-h
microalbuminuria and use of diuretics, inhibitors of the renin–angiotensin system
(b-blockers, ACE inhibitors and angiotensin type 1 receptor blockers), vasodilators (cal-
cium channel blockers and a-blockers). Models with eGFR at follow-up as a dependent
variable were additionally adjusted for follow-up duration. Significance of the associa-
tions: *P 0.05, †P 0.01, ‡P 0.001, §P 0.0001.
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and MCP-1 (P< 0.0001). TNF-a (P 0.013), but not NGAL
(P 0.57) and IL-6 (P 0.39), outperformed the two adhesion
molecules.
A single variable derived by principle component analysis
from VCAM-1, MCP-1, TNF-R1 and TNF-a, which were
highly intercorrelated (0.14 r 0.79; P< 0.0001) yielded an
AUC of 0.78 (95% CI 0.75–0.83), which was not greater than
the AUC of TNF-R1 considered alone (P¼ 0.68).
Longitudinal analyses in 500 participants with follow-up
In the longitudinal analyses, eGFR (continuous) or eGFR
stage at follow-up were related to the biomarkers measured at
baseline. The models were adjusted for the same baseline co-
variables as in the cross-sectional analyses (Supplementary data,
Table S6) and additionally included follow-up duration.
Consistent with the cross-sectional analysis, eGFR at follow-up
was inversely associated with the baseline biomarkers, with as-
sociation size of 2.76 for VCAM-1, 2.90 for MCP-1, 1.28
for NGAL, 5.34 for TNF-R1, 6.99 for TNF-a and 1.31 for
IL-6 (Table 3 and Figure 2). The hazard ratios expressing the
risk of having eGFR<60mL/min/1.73 m2 (n¼ 33) at follow-up
in participants with eGFR60mL/min/1.73 m2 at baseline
(n¼ 412) were significant for baseline VCAM-1, TNF-a and
VEGF, with estimates of 1.30 (P¼ 0.0004), 1.15 (P¼ 0.027) and
1.07 (P¼ 0.044), respectively. Finally, additional adjustment for
sex and age of both the cross-sectional and longitudinal analyses
did not materially change the results reported in Table 4 and
Figure 2.
FIGURE 2: –Log10(P) probability plot of the multivariable-adjusted associations of eGFR (continuous or categorical) with the baseline bio-
markers. In categorical analyses, eGFR<60 and60mL/min/1.73 m2 were contrasted. All analyses were adjusted for mean arterial pressure,
waist:hip ratio, smoking, plasma glucose, c-glutamyltransferase, total:HDL cholesterol ratio, 24-h microalbuminuria and use of diuretics, inhib-
itors of the renin–angiotensin system (b-blockers, ACE inhibitors and angiotensin type 1 receptor blockers), vasodilators (calcium channel
blockers and a-blockers), lipid-lowering drugs and biomarker at baseline. The longitudinal analyses were additionally adjusted for follow-up
duration.
FIGURE 3: AUC for the adhesion molecules and inflammation
markers in the discrimination between eGFR Stage 3 versus Stage
2 in the baseline study. Vertical bars denote the 95% CI. The
shaded area represents the 95% CI of the AUC for 24-h microalbu-
miuria. AUCs for the biomarkers were ordered by magnitude.
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DISCUSSION
To our knowledge, our study is the first to assess in a general
population [31] the association of eGFR as continuous and cate-
gorical variables with circulating inflammation markers and ad-
hesion molecules. The key findings can be summarized as
follows: (i) in cross-sectional analyses, eGFR evaluated on a
continuous scale was inversely associated with adhesion mole-
cules VCAM-1 and MCP-1 and the inflammation markers
TNF-R1 and TNF–a; (ii) the odds of having eGFR<60mL/
min/1.73 m2 at baseline as compared with60mL/min/1.73
m2 increased with higher serum levels of VCAM-1, MCP-1,
TNF-R1 and TNF–a; (iii) TNF-R1, compared with 24-h albu-
minuria, VCAM-1 and MCP-1 best discriminated eGFR<60
versus60mL/min/1.73 m2 and combining these highly in-
tercorrelated serum markers into a single variable did not en-
hance discrimination and (iv) prospective analyses covering
5 years of follow-up in about one-third of the study popula-
tion were confirmatory.
Experimental studies in vitro [8–10] and in mice [11, 12] jus-
tified the hypothesis that we set out to test in the current popu-
lation study. Our observations are in keeping with the large
body of evidence showing that TNF-a, also called TNF, is a cell
signalling cytokine that plays a pivotal role in mediating inflam-
mation. Binding of TNF-a to TNF-R1 stimulates the transcrip-
tional activity of nuclear factor kappa B (NF-jB), which in turn
leads to increased expression of adhesion molecules, including
VCAM-1 and MCP-1, in endothelial cells [32, 33]. This path-
way (Supplementary data, Figure S1) and the high correlations
between the four circulating markers explain why a linear com-
bination of TNF-R1, TNF-a, VCAM-1 and MCP-1 did not en-
hance the discrimination of eGFR<60 versus 60mL/min/1.
73 m2. We did not adjust significance levels for multiple testing.
The theoretical basis for applying a correction for multiple test-
ing is that chance serves as the first-order explanation for
observed associations [34]. However, if, as in the present study,
the biomarkers are highly intercorrelated, each new test does
not provide a completely independent chance for a type 1 error,
making adjustment for multiple testing inappropriate [34].
Our current study moves beyond the state of the art by trans-
lating findings from experimental studies [8–12] and knowledge
about molecular pathways to people representative of a general
population [32, 33]. Moreover, we searched PubMed for rele-
vant publications without limitation of publication date or lan-
guage, using terms ‘eGFR, biomarkers, human’ or ‘renal
function, biomarkers, human’. We screened papers by title or
abstract to identify full-text reports that might be relevant to
our hypothesis. We did a full-text review of 29 articles. None of
these studies analysed the association of renal function with a
set of circulating adhesion molecules in a general population.
Thus our study provides the first evidence that circulating adhe-
sion molecules, in particular VCAM-1, are inversely associated
with eGFR and predict the incidence of eGFR decline in the
general population.
In keeping with recent recommendations [35] and previous
studies [24, 36], in our study we applied an early renal endpoint
defined as an eGFR<60mL/min/1.73 m2 without short-term
confirmation or association with other manifestations of renal
disease. The Framingham investigators used a similar outcome
measure [24, 25]. Among 2585 participants free of pre-existing
renal disease, 244 (9.4%) developed clinically overt kidney dis-
ease during a mean follow-up of 18.5 years. Furthermore,
FIGURE 4: ROC curves for prediction of eGFR decline from60
to<60mL/min/1.73 m2. Blue, green, red and black lines identify 24-
h microalbuminuria and circulating VCAM-1, MCP-1 and TNF-R1
at baseline, respectively.
Table 4. Multivariable-adjusted associations of eGFR stage with the bio-
markers measured at baseline
Biomarker eGFR (2 versus 3)
at baseline
(1200 versus 138),
odds ratio
(95% CI)
DeGFR (2!3)
from baseline to
follow-up
(412 versus 33),
hazard ratio
(95% CI)
Adhesion molecules
VCAM-1 (ng/mL) 1.77 (1.39–2.26)§ 1.30 (1.12–1.49)‡
ICAM-1 (ng/mL) 1.37 (0.96–1.75) 1.23 (1.06–1.42)†
E-selectin (ng/mL) 0.96 (0.77–1.19) 1.10 (0.99–1.22)
P-selectin (ng/mL) 1.28 (0.99–1.64) 1.17 (1.02–1.32)†
MCP-1 (pg/mL) 1.32 (1.16–1.51)§ 0.99 (0.92–1.08)
Inflammation markers
CRP (ng/mL) 1.08 (0.98–1.20) 1.06 (1.01–1.12)*
NGAL (ng/mL) 1.26 (1.12–1.43)‡ 1.07 (1.00–1.16)
TNF-R1 (ng/mL) 1.49 (1.31–1.71)§ 1.01 (0.92–1.08)
TNF-a (pg/mL) 1.45 (1.25–1.69)§ 1.15 (1.02–1.31)*
IL-6 (pg/mL) 1.20 (1.08–1.34)‡ 1.03 (0.96–1.09)
IL-8 (pg/mL) 1.14 (1.00–1.30) 0.96 (0.89–1.04)
VEGF (pg/mL) 1.12 (1.01–1.25)* 1.07 (1.01–1.13)*
DCKD, change in CKD stage from baseline to follow-up. eGFR calculated according to
the CKD-EPI formula [22]. Stages of CKD were defined according to the National
Kidney Foundation KDOQI guideline [23]. Hazard ratios were computed excluding 55
participants who from baseline to follow-up regressed from CKD Stage 2 to 1 or from
Stage 3 to 2 or who maintained Stage 3. Of the remaining 445 participants, 33 (7.4%)
progressed from Stage2 to Stage3. Estimates, given with 95% CI, express the relative
risk associated with a doubling of the marker. All analyses were adjusted for baseline vari-
ables, including mean arterial pressure, waist:hip ratio, smoking, plasma glucose, c-gluta-
myltransferase, total:HDL cholesterol ratio, 24-h microalbuminuria and use of diuretics,
inhibitors of the renin–angiotensin system (b-blockers, ACE inhibitors and angiotensin
type 1 receptor blockers), vasodilators (calcium channel blockers and a-blockers).
Significance of the associations: *P 0.05, †P 0.01, ‡P 0.001, §P 0.0001.
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|Matsushita et al. [36] conducted a meta-analysis to investigate
the association of eGFR with all-cause and cardiovascular mor-
tality in 21 general population cohorts. They reported that the ad-
justed hazard ratios for all-cause mortality at an eGFR of 60
compared with 95mL/min/1.73 m2 was 1.18 (95% CI 1.05–1.32).
In line with our current observations, cross-sectional [37] or
longitudinal [38] analyses of several population studies identi-
fied circulating NGAL and TNF receptors as circulating bio-
markers inversely associated with eGFR [37, 38] or predictive of
eGFR decline [38]. Similar findings were obtained in a case–
control study in patients with CKD Stages 2–4 or end-stage re-
nal disease [5]. In the Chronic Renal Insufficiency Cohort study
[39], over a median follow-up time of 6.3 years, 899 of 3430 pa-
tients reached the composite endpoint of a50% decline in
eGFR or onset of end-stage renal disease. In multivariable-
adjusted analyses, accounting for baseline eGFR and other co-
variables, the hazard ratios for the composite outcome were
greater for patients in the highest quartile of IL-6 [1.44 (95% CI
1.17–1.77)] and TNF-a [1.94 (95% CI 1.52–2.47)] compared
with those in the respective lowest quartiles. CRP is a widely
used inflammatory biomarker. However, the association of
eGFR with CRP in the current literature is inconsistent [32, 33].
In line with these reports [32, 33], our study did not identify CRP
as being associated with eGFR or predictive of eGFR decline.
Whereas the available literature frequently addresses the as-
sociation of renal dysfunction with circulating inflammation
markers, few studies have focused on adhesion molecules [31,
40]. Among 4128 older people enrolled in the Cardiovascular
Health Study (mean age 72 years), 1059 (25.7%) had an annual
decline in eGFR derived from cystatin C exceeding >3mL/
min/1.73 m2. Over 7 years of follow-up, only serum albumin
predicted a rapid decline of eGFR, with a multivariable-
adjusted odds ratio per 1 SD increment of 1.14 (95% CI 1.06–
1.23). CRP (n¼ 4113), IL-6 (n¼ 3813), ICAM–1 (n¼ 1409)
and six other inflammatory markers (1628< n< 4125) were
not predictive. In a cross-sectional study of 1950 Asians with
type 2 diabetes [40], eGFR declined and the urinary
albumin:creatinine ratio increased with higher plasma
VCAM-1 levels, whereas the corresponding associations with
plasma ICAM-1 levels were not significant. In our current
study, why eGFR is inversely associated with VCAM-1 but not
ICAM-1 remains to be elucidated. One possible explanation is
the differential expression or kinetics of VCAM-1 and ICAM-
1 in response to inflammatory stimuli according to the under-
lying disease or anatomical location [41, 42]. For instance, in
atherosclerosis, VCAM-1 is mainly expressed in lesions,
whereas ICAM-1 expression extends into lesion-protected and
predisposed sites [41]. Our literature search identified one
cross-sectional Japanese study [43] involving 860 residents of
a fishing community in which, with adjustments applied for
sex and age, eGFR declined with MCP-1. A similar inverse as-
sociation between eGFR and serum MCP-1 was reported
among 479 African Americans with type 2 diabetes with a
more complete adjustment including covariables of sex, age,
body mass index, smoking, hemoglobin A1c and low-density
lipoprotein cholesterol [44]. However, the only inflammation
biomarker considered in these two MCP-1 studies [43, 44] was
the white blood cell count [43].
The present study must be interpreted within the context of
some potential limitations. First, circulating biomarkers only
provide a snapshot of a state that involves the whole body and
are not necessarily representative of a process that is specific to
the kidneys. Observational studies can also not infer causality.
However, studying the local expression of these biomarkers in re-
lation to histopathological lesions in human kidneys is not prac-
ticable. Only experimental studies can clarify how adhesion
molecules are involved in glomerular disease either as mediators
or bystanders. Second, only 500 of our 1338 participants were
followed up, so our longitudinal analyses might have been un-
derpowered. At the time of writing of this article, follow-up of ex-
amination cycle B participants was too short for a reassessment
of their renal function. Nonetheless, examination cycle A partici-
pants with and without follow-up had similar baseline character-
istics. Third, we did not measure the serum biomarkers at the
time of reassessment of eGFR. Finally, in contrast to previous
studies in CKD patients, we did not measure NGAL in urine, but
only in serum, which might have led to an underestimation of
the association of renal dysfunction with this biomarker.
CONCLUSIONS
Our data demonstrate that eGFR is inversely associated with the
serum levels of adhesion molecules VCAM-1 and MCP-1 and
the inflammation biomarkers TNF-R1 and TNF-a. Binding of
TNF-a with its cellular receptor initiates a signalling pathway
leading to expression of the adhesion molecules (Supplementary
data, Figure S1). The proximal role of the inflammation markers
in this pathway might explain why TNF-R1 and TNF-a outper-
formed VCAM-1 and MCP-1 in differentiating between eGFR
Stage2 and3. Further studies are required to confirm our
findings in other populations and to establish whether the circu-
lating biomarkers reflect a systemic inflammatory condition or
are specific forerunners of glomerular impairment.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxfordjour
nals.org.
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ABSTRACT
Background. Hypertension is a leading cause of chronic kidney
disease (CKD) and a decrease in glomerular filtration rate (GFR)
is associated with a higher prevalence of hypertension and an
increased proportion of suboptimal blood pressure (BP) control.
Methods.To investigate characteristics associatedwithGFRdecline,
we selected 4539 hypertensive patients from the Campania Salute
Network (mean age 536 11 years) with at least 3 years of follow-up
(FU) and no more than Stage III CKD. GFR was calculated at base-
line and at the last available visit using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation. GFR decline was
defined as a30% decrease from initial GFR for patients in Stage III
CKD or by a composite 30% decrease from baseline and a final
value of<60 for those< with Stage III or higher CKD.
Results.At a mean FU of 7.5 years, 432 patients (10%) presented
with GFR decline. Those patients were older, more likely to be
diabetic, with lower GFR and ejection fraction, higher systolic
and lower diastolic BP and higher left ventricular (LV) mass and
relative wall thickness at baseline; during FU, patients with GFR
decline exhibited higher systolic BP, took more drugs and devel-
oped more atrial fibrillation (all P< 0.02). The probability of
GFR decline was independently associated with older age, preva-
lent diabetes, baseline lower GFR, higher systolic BP during FU,
FU duration, increased LVmass and incident AF with no impact
from antihypertensive and antiplatelet medications.
Conclusions. During antihypertensive therapy, kidney function
declines in patients with initially lower GFR, increased LV mass
and suboptimal BP control during FU.
Keywords: chronic renal failure, GFR decline, hypertension,
LV hypertrophy, target organ damage
INTRODUCTION
Hypertension and chronic kidney disease (CKD) represent a
global public health burden due to their worldwide epidemic
prevalence and their close association [1–3]. Hypertension is a
leading cause of CKD and a decrease in glomerular filtration
rate (GFR) is associated with a higher prevalence of hyperten-
sion and an increased proportion of suboptimal blood pressure
(BP) control [4, 5]. In addition, based on evidence from end-
stage renal disease (ESRD) registries [2], the link between
hypertension and CKD has been evaluated in large unselected
population studies, with conflicting results about the role of
hypertension on GFR decline [6–8]. Overall, there is little infor-
mation on the development and/or progression of CKD over
time during the natural history of treated arterial hypertension.
Analysis of CKD progression can allows us to determine factors
facilitating the worsening of arterial hypertension and to iden-
tify phenotypes at risk. Accordingly, we analysed factors associ-
ated with GFR decline in a large registry of treated hypertensive
outpatients from southern Italy.||
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